Clinical Research Advantage Acquires Late Phase Division of Comprehensive Clinical Development
Clinical Research Advantage (CRA), a network of clinical trial sites, has further expanded its geographic and therapeutic reach by acquiring the late phase division of Comprehensive Clinical Development (CCD).
Clinical Research Advantage (CRA), a network of clinical trial sites, has further expanded its geographic and therapeutic reach by acquiring the late phase division of Comprehensive Clinical Development (CCD). This transaction will allow CRA to offer pharmaceutical sponsors and contract research organizations an across-the-board solution for their diverse clinical research needs.
Clinical Research Advantage includes 63 sites listed under “CRA” and “Radiant Research.” Both brands are known as leaders in Phase II-IV clinical trials. CRA focuses on on family practice and general medicine, while Radiant conducts multi-specialty and consumer trials. Comprehensive Clinical Development works in psychiatric clinical trials, specifically in the areas of schizophrenia, bipolar disorder, depression, and Alzheimer’s disease. CCD has participated in the development of every major psychiatric drug that has been developed over the past 10 years.
“By adding Comprehensive Clinical Development to the CRA family of trial sites we are able to increase our capabilities to meet the needs of the growing pharmaceutical marketplace,” said Mark S. Hanley, Chief Executive Officer of CRA. “We are excited about this partnership and the opportunity to move into new therapeutic areas of clinical research. CCD has an impressive track record in psychiatric trials, and we see it as an ideal partner as we continue to expand our operations.”
Based in Miramar, Fla., CCD was founded in 1998. The company operates four independent sites in Atlanta, Ga., Cerritos, Calif., Holliswood, N.Y., and Washington, D.C. The combined companies will continue to function under the names Clinical Research Advantage and Comprehensive Clinical Development, but will be looking to integrate and streamline their operations where appropriate.
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
